N-(3-(4-hexahydropyridyloxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridyl)ethyl)amino)-3-pyridinecarboxamide | 453565-07-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3-(4-hexahydropyridyloxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridyl)ethyl)amino)-3-pyridinecarboxamide
• 英文别名: N-(3-(4-piperidinyloxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridinyl)ethyl)amino)-3-pyridinecarboxamide；N-(3-(4-piperidyloxy)-5-(trifluoromethaneyl)phenyl)-2-((2-(3-pyridyl)ethyl)amino)-3-pyridinecarboxamide；(3-(4-piperidinyloxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridinyl)ethyl)amino)-3-pyridinecarboxamide；N-(3-(4-piperidinoxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridyl)ethyl)amino)-3-pyridinecarboxamide；N-(3-(4-piperidyloxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridyl)ethyl)amino)-3-pyridinecarboxamide；N-[3-piperidin-4-yloxy-5-(trifluoromethyl)phenyl]-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide
• CAS: 453565-07-6
• 化学式: C₂₅H₂₆F₃N₅O₂
• 分子量: 485.509
• InChiKey: HXCBNDBUQHHIMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  88.2
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS<br/>[FR] COMPOSÉS CONDENSÉS DE PYRIDINE, DE PYRIMIDINE ET DE TRIAZINE EN TANT QU'INHIBITEURS DU CYCLE CELLULAIRE
  申请人：AMGEN INC

  公开号：WO2009085185A1

  公开（公告）日：2009-07-09

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

  提供了一种化合物、药物组合物和方法，用于治疗CDK4介导的疾病，如癌症。所述化合物是融合的吡啶、嘧啶和三嗪衍生物。
• [EN] SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006012374A1

  公开（公告）日：2006-02-02

  The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

  本发明提供了一类化合物，包括其药用可接受的衍生物，用于治疗血管生成和相关疾病，如癌症。其中R为从7-异喹啉基、2-甲基-3-氧代-2,3-二氢吲哚-6-基、[1,6]-萘啶-3-基、[1,7]-萘啶-2-基、1-氧代-2,3-二氢苯并呋喃-4-基、3-氧代-2,3-二氢苯并呋喃-5-基、二氢苯并二氧杂环基、6-喹唑啉基、2-氨基-6-喹唑啉基、4-甲氨基-6-喹唑啉基、2,4-二氨基-6-喹唑啉基、3-氧代-3,4-二氢-1,4-苯并噁嗪-6-基、2,2-二氟-1,3-苯并二氧杂环-5-基和2,2,3,3-四氟-2,3-二氢-1,4-苯并二氧杂环-6-基中选择的9-或10-成员杂环基，其中每个基可选择地被一个或多个来自卤素、卤代烷基、C1-6烷基、C2-8烯基、C2-8炔基、N-二甲氨基-C1-6-烷基、N-二甲氨基-C1-6-烷氧基、氨基、烷基-羰基氨基、吗啉磺酰基、氨基磺酰基、噁唑基、吡咯基、吗啉基、羧基、氰基和乙酰基的取代基取代；其中式I中的R1从未取代或取代的苯基、5-6成员杂芳基、9-10成员双环杂环基和11-14成员三环杂环基中选择，式II中的R1从特定的双环杂环基中选择。
• [EN] GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS<br/>[FR] PYRIDINES/PYRIMIDINES AMINO SPIROCYCLIQUES ET DISUBSTITUÉES PAR GEM EN TANT QU'INHIBITEURS DE CYCLE CELLULAIRE
  申请人：AMGEN INC

  公开号：WO2009126584A1

  公开（公告）日：2009-10-15

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are gem-disubstituted or spirocyclic pyridine, pyrimidine and triazine derivatives.

  提供了一些化合物、药物组合物和方法，这些化合物、药物组合物和方法可用于治疗CDK4介导的疾病，如癌症。所述化合物是 gem-二取代或螺环的吡啶、嘧啶和三嗪衍生物。
• [EN] HETEROCYCLES AS PROTEIN KINASE INHIBITORS<br/>[FR] HÉTÉROCYCLES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：AMGEN INC

  公开号：WO2009143477A1

  公开（公告）日：2009-11-26

  Selected fused imidazole or triazole derivatives are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的融合咪唑或三唑衍生物对于预防和治疗疾病，如HGF介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药用可接受盐，以及用于预防和治疗涉及癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的工艺以及在此类工艺中有用的中间体。
• Substituted heterocycles and methods of use
  申请人：Bellon Steven

  公开号：US20080214544A1

  公开（公告）日：2008-09-04

  Selected compounds are effective for prophylaxis and treatment of diseases, such as c-met mediated diseases and/or HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗c-met介导的疾病和/或HGF介导的疾病有效。本发明涵盖了新型化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗涉及癌症等疾病和其他不适或情况的方法。本发明还涉及制备这些化合物的过程，以及在这些过程中有用的中间体。